Prime Therapeutics has released a report detailing the rising cost of autoimmune drugs. Read More »

The American Pharmacists Association recently hosted 650 pharmacists at its 2016 Joint Federal Pharmacy Seminar in Oxon Hill, Maryland. Read More »

Janssen Pharmaceuticals Inc.'s results of its XARELTO Phase 3b PIONEER AF-PCI clinical trial and new research involving INVOKANA will be featured in presentations at the American Heart Association Scientific Sessions, being held through Wednesday in New Orleans. Read More »

In the dance between drug and insurance companies over the cost of medicines and which ones should be prescribed, step therapy or “fail first” policies are increasingly popular. Read More »

Mallinckrodt Pharmaceuticals' OFIRMEV injection has received a Prior Approval Supplement from the U.S. Food and Drug Administration. Read More »

Walgreens Boots Alliance Inc. was recently honored by the American Ireland Fund at the 32nd Annual Chicago Dinner by awarding it with the American Ireland Fund Corporate Social Responsibility Award. Read More »

Innovus Pharmaceuticals and Elis Pharmaceuticals have finalized a second exclusive license and distribution agreement for Zestra. Read More »

Roche's VENTANA ALK (D5F3) CDx Assay has received approval from the U.S. Food and Drug Administration to be used in conjunction with the VENTANA BenchMark ULTRA automated slide stainer. Read More »

Bayer has submitted its supplemental New Drug Application for Stivarga tablets to the U.S. Food and Drug Administration. Read More »

Jordan Howard, the leading rusher for the Chicago Bears, attended the 2016 Pulmonary Fibrosis Foundation’s volunteer meeting where he dedicated himself to fighting pulmonary fibrosis. Read More »

The U.S. Food and Drug Administration has approved Propeller Health's platform for use with GSK’s Ellipta inhaler. Read More »

The National Pharmaceutical Council Board of Directors has appointed Dr. Joshua Ofman as its new vice chairman. Read More »

AbbVie's oral poly polymerase inhibitor valiparib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »

Kedrion Biopharma and Kamada's Biologics License Application for human anti-rabies immunoglobulin therapy has been accepted for review by the U.S. Food and Drug Administration. Read More »

Eli Lilly and Co.'s analysis of its Phase 3 baricitinib trial efficiency and safety data, as well as that of other Phase 2 trials, will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting, which is being held on Nov. 11-16 in Washington, D.C. Read More »

HalioDx SAS has released a report detailing the progress being made by its clinical research services. Read More »

URAC has accredited CVS Caremark's Pharmacy Adviser counseling program run by the Health Call Center and its Pharmacy Benefit Management and Drug Therapy Management. Read More »

ACADIA Pharmaceuticals' ENHANCE-1 Phase III trial involving pimavanserin has been initiated to assess the ability of pimavanserin to treat schizophrenia in patients who have had a negative response to the antipsychotic therapies currently in use. Read More »

Anthera Pharmaceuticals' Phase 2 BRIGHT-SC trial data has been selected as a poster presentation at the 2016 American Society of Nephrology’s Kidney Week Annual Meeting. Read More »

Momenta Pharmaceuticals and Mylan N.V.'s first patient in its Phase 1 study of M834 has been dosed. The trial will evaluate M834's pharmacokinetics, safety and immunogenicity. Read More »